chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Rash on her head, which she developed after her 1st Moderna vaccination, and 2nd Moderna vaccine it got out of control; This spontaneous case was reported by a consumer and describes the occurrence of RASH (Rash on her head, which she developed after her 1st Moderna vaccination, and 2nd Moderna vaccine it got out of control) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for Prophylactic vaccination.    Co-suspect products included non-company products DUPILUMAB (DUPIXENT) injection for Rash and DUPILUMAB (DUPIXENT) injection for Rash.    The patient's past medical history included Basal cell carcinoma. Concurrent medical conditions included Drug hypersensitivity (Violently allergic to Aleve and Motrin) and Urticaria. Concomitant products included FLUOCINONIDE for Rash.   In 2021, the patient started DUPILUMAB (DUPIXENT) (Subcutaneous) 300 milligram every two weeks. On 09-Sep-2021, the patient started DUPILUMAB (DUPIXENT) (Subcutaneous) 600 milligram. On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 2 dosage form. On an unknown date, the patient experienced RASH (Rash on her head, which she developed after her 1st Moderna vaccination, and 2nd Moderna vaccine it got out of control). The patient was treated with IBUPROFEN (ADVIL [IBUPROFEN]) for Illness and Tendon discomfort, at an unspecified dose and frequency. At the time of the report, RASH (Rash on her head, which she developed after her 1st Moderna vaccination, and 2nd Moderna vaccine it got out of control) outcome was unknown.            This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.   This case was linked to MOD-2021-624324 (Patient Link).
Information has been received from a 28-year-old female registered nurse who was vaccinated as a child with a dose of measles virus vaccine live (Enders-Edmonston) (+) mumps virus vaccine live (Jeryl Lynn) (+) rubella virus vaccine live (Wistar RA 27/3). A "recent" titer was negative for measles and rubella. Unspecified medical attention was sought. No further information was available. There was no product quality complaint. Additional information has been requested.
ON AND OFF TINNITUS; This spontaneous report received from a patient concerned a 79 year old female. The patient's height, and weight were not reported. The patient's past medical history included gall bladder surgery, and cataract extraction, and concurrent conditions included hypertension, general osteoarthritis, high cholesterol, osteopenia, non alcohol user, and non smoker, and other pre-existing medical conditions included the patient had no known allergies and no history of drug abuse or illicit drug use. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, and batch number: 1808982, expiry: UNKNOWN) dose was not reported, administered on 26-MAY-2021 for prophylactic vaccination. No concomitant medications were reported.  On 02-JUN-2021, the subject experienced on and off tinnitus. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from on and off tinnitus. This report was non-serious.
just had a half dose for her first shot.; mild malaise; slight fever; chills; This is a spontaneous report from a Pfizer sponsored program. A contactable female consumer (patient) of an unspecified age received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number: unknown), via an unspecified route of administration as single dose on 10Mar2021 for COVID-19 immunization. The patient's concomitant medications and medical history were not reported. She had the first dose on 03Mar2021 and had mild malaise, slight fever and chills and just had a half dose for her first shot. There were unaddressed medical questions referred or forwarded to Medical Information. The outcome of the events was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
expired Bexsero administered; This case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 17-year-old female patient who received Men B NVS (Bexsero) (batch number abxb39ab, expiry date 31st July 2022) for prophylaxis.   Co-suspect products included meningococcal B recom vaccine + aloh + omv pre-filled syringe device (Bexsero Pre-Filled Syringe Device) injection syringe for prophylaxis.   On 10th August 2022, the patient received the 2nd dose of Bexsero and Bexsero Pre-Filled Syringe Device. On 10th August 2022, unknown after receiving Bexsero and Bexsero Pre-Filled Syringe Device, the patient experienced expired vaccine used. On an unknown date, the outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 11-AUG-2022 Reporter's Comment: The reporter was medical assistance. The reporter reported that, a patient was administered with an expired dose of Bexsero . No adverse event was reported. The reporter consented to follow up by phone. Additional Supportive Information: The reporter reported that, a patient was administered with an expired dose of Bexsero, which led to expired vaccine used. The case US2022118004 was identified as duplicate of US2022118010. The case US2022118010 would be voided, and all the future correspondence would be added in this case US2022118004 which stands as a case of record for this patient.
This spontaneous report as received from a healthcare worker refers to a 4 year old patient. The reporter stated that patient received expired dose of PROQUAD (dose 2 in series) (0.5 ml, subcutaneously) (dose 2 in series). The reporter stated PROQUAD had expiry of 08-JUL-2014 and was administered on 21-JUL-2014. No adverse effects reported. Additional information has been requested.
Expired Dose Administered; This non-serious case was reported by a other health professional via call center representative and described the occurrence of expired vaccine used in a 15-month-old male patient who received DTPa (Infanrix) (batch number 7KM94, expiry date 10-JUN-2023) for prophylaxis.   On 10-JUL-2023, the patient received Infanrix. On 10-JUL-2023, an unknown time after receiving Infanrix, the patient experienced expired vaccine used (Verbatim: Expired Dose Administered). The outcome of the expired vaccine used was unknown.   This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences.   Additional Information: GSK Receipt Date: 19-JUL-2023 The reporter was clinical manager. The Vaccine Administration Facility was the same as Primary Reporter. The reporter consented to follow up via postal. The reporter stated that an expired dose of Infanrix was administered to a patient, which led to expired vaccine used.
Dose 1 given 2/4/2021 lot # N/A Pfizer Patient died at Medical center on 2/23/2022 from Covid 19, and heart failure
Started feeling ill to stomach 5 hours after vaccination. Started violently throwing up and discarded everything in my stomach including stomach acid about 11 1/2 hours after vaccination. Fever started 1/12/2023 about 9 am at 100.8.  Took Motrin to bring fever down. It is now 1/13/2023 at 3:04 pm and I went to urgent care about 30 mins ago being told this did seem like a reaction. I am fever free but still sick to my stomach and still throwing up if I move around too quickly or too often and also am getting cold chills and sweating in a shirt and pants in 46 degree weather. I have never had a reaction to a vaccination before.
redness, 3-4 days p/inject; lump, very hard; tender; low grade fever;
I had a MVA on December 19 2000. After physical therapy the pain in my neck was down to a 1. Then after the 2nd dose of moderna about 15 hours after injection I woke up Sunday morning (the next day) and I could barely get out of bed from the pain in my neck. I could not move my neck and the pain was radiating down my left arm. The next day (Monday) I was feeling better and had more movement in my neck but still lots of pain. I went to the PA on Monday and got checked out. I still had strength but mobility was very little. I still have the pain and radiation down arm.
The patient received third/ booster dose of BNT162B2; Arm pain; Redness; Lump-like swelling.; Headache everyday; Chills; Sweating enough to soak sheets and pillow for several days.; Diarrhea; Feeling sick; This is a spontaneous report from a contactable consumer, the patient. A 63-year-old non-pregnant female patient received third dose (booster dose) of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: FH8020) via an unspecified route of administration in the left arm on 02Nov2021 at 15:00 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included non-hodgkins follicular lymphoma (6 months post rituxan maintenance). The patient received other vaccine within four weeks prior to the COVID vaccine. The patient had no known allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Concomitant medications included influenza vaccine (FLU SHOT) in the left arm on 19Oct2021 for immunisation and venlafaxine hydrochloride (EFFEXOR), atorvastatin calcium (LIPITOR) and unspecified synthetic; all from an unknown date for unknown indication and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the left arm on 09Mar2021 at 13:30 (at the age of 63-years-old) and received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the left arm on 30Mar2021 at 13:30 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. The patient previously took rituximab (RITUXAN) from an unknown date for follicular lymphoma and unknown if ongoing. On 02Nov2021, the patient experienced arm pain with redness and lump-like swelling, headache every day, chills, sweating enough to soak sheets and pillow for several days, diarrhea and feeling sick. The events arm pain with redness and lump-like swelling, headache everyday chills, sweating enough to soak sheets and pillow for several days, diarrhea and feeling sick did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events arm pain with redness and lump-like swelling, headache everyday chills, sweating enough to soak sheets and pillow for several days, diarrhea and feeling sick. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events arm pain with redness and lump-like swelling, headache everyday chills, sweating enough to soak sheets and pillow for several days, diarrhea and feeling sick was not resolved at the time of this report.
given Hep A on 8/24/06. Vomiting noted that evening plus low grade fever.
This literature marketed report as received from the author of a public article. It was reported that current literature on the effectiveness of measles post-exposure prophylaxis (PEP) was limited and variable. The authors examined the effectiveness of measles, mumps, and rubella vaccine (MMR) and immune globulin (IG) PEP among children exposed to measles during an outbreak in 2013. Contacts were identified by the Department of Health and Mental Hygiene between 13-MAR-2013 and 30-JUN-2013. Immunity to measles and receipt of PEP was determined for contacts. PEP effectiveness [(1- relative risk of developing measles) x 100] was calculated for MMR, IG, and any PEP (MMR or IG) for nonimmune contacts aged less than 19 years. Of the contacts included, 44 received MMR PEP and 77 received IG PEP. Effectiveness of MMR PEP was 83.4% (95% confidence interval [CI], 34.4%, 95.8%). No contact who received IG PEP developed measles; effectiveness of IG PEP was 100% (approximated 95% CI, 56.2%, 99.8%). Effectiveness of receiving any PEP (MMR or IG) was 92.9% (95% CI, 56.2%, 99.8%). The authors concluded that contacts who received PEP were less likely to develop disease. Their findings supported current recommendations for administration of PEP following exposure to measles. These results highlighted the importance of a rapid public health outbreak response to limit measles transmission following case identification. This case refers to an infant patient of unknown gender, aged 6 to less than 12 months. Information regarding relevant medical history, concurrent condition and concomitant medications were not reported. In approximately 2013, the patient was vaccinated with measles, mumps, and rubella virus vaccine (manufacturer unknown) (dose, route and lot # not reported) for measles PEP. After receiving MMR, on an unknown date, the patient developed measles. The patient had generalized maculopapular rash with respiratory symptoms, but virus genotyping was not performed, and vaccine-strain virus could not be ruled out as the cause of symptoms. Developing measles after MMR was considered as effectiveness issues by the author. The outcome of the events was unknown. Upon internal review, measles after MMR was considered to be medically significant. This is one of two reports received from the same article (related case ID: 1712USA007366).; Sender's Comments: US-009507513-1712USA007366:
Information has been received from a medical assistant referring to multiple unspecified patients of unknown age and gender. It was reported that these patients were administered doses of improperly stored GARDASIL (lot# K004205, Exp date 12-JAN-2017) (dose and route not reported). It was reported that 1 dose was administered on 10-FEB-2015, 1 dose on 12-FEB-2015, 1 dose on 26-FEB-2015, 1 dose on 06-MAR-2015, 2 dose on 17-MAR-2015 and 1 dose on 25-MAR-2015. This is one of the several reports with the same reporter. Additional information has been requested.
Initial report was received on 10 February 2011 from a health care professional. A 51-year-old female had received an intramuscular left deltoid injection of ADACEL, lot number U3491CA (sanofi pasteur Ltd. lot number C3637) on 14 December 2010 and the same day (also reported as 15 December 2010), felt "run down and feverish". The second day she reported she started to cough and had redness, pain scale of a three and was itchy at the site. The patient was evaluated by a physician and prescribed a medication for the cough but never took it. The symptoms subsided. Concomitant medications included Medroxyprogesterone and Estradiol. No further information was available at the time of the report. The patient's outcome was reported as recovered (date not reported). Follow-up information was received from a health care professional on 12 April 2011. The patient's adverse event began on 14 December 2011. Her past medical history was reported as none and she had no illness at the time of vaccination. The reporter states that the patient was called on 12 April 2011 and reported that she had no problems after the report. No further information was available at the time of the report. The patient's outcome remained as recovered. Documents held by sender: none.
This spontaneous report was received from a medical assistant and refers to a patient of unknown age an gender. The patient's medical history, concurrent conditions and concomitant therapies were not reported. The medical assistant reported that on 27-JAN-2017, an expired dose of ROTATEQ lot # L013197, expiration date 26-JAN-2017 (dose and route were not reported) for prophylaxis, was administered to the patient. No adverse effects were reported. Additional information has been requested.
Patient states that a few days after receiving COVID Pfizer vaccine they started to notice a pain on their upper back focused on the right side below the shoulder blades. Over the next few days the pain felt as though it had migrated towards her lungs. She would feel a sharp pain when taking deep breaths. She notified the pharmacy on 8/7/21 and symptoms first started on 8/4/21.
20 year old, male patient came in for his appointment for Janssen COVID vaccine. Patient filled out the vaccine questionnaire, and we discussed patient questions and common side effects. Patient did not state any adverse reaction to previous vaccine or fainting history on the vaccine questionnaire. Patient was given vaccine in left arm. Shortly after receiving vaccine, patient states, "uh-oh it's happening again." I asked patient what was happening and he stated, "this happened to me when I got a blood draw. I fainted."  I told patient to take some deep breaths, patient started to stare off to the ceiling and his pupils were dilated and his head fell back in the chair towards the ceiling. His legs body became stiff and he lost consciousness in the chair.  I called for help and she came to assist me in the immunization room. I ran to get him a water while the pharmacy called for 911. He regained consciousness quickly, within a minute.  Emergency response came quickly and attended to him and took his blood pressure and vitals. He was able to drink water and respond to all questions. He refused to be taken to the hospital and did not think he needed any additional medical attention. He was advised to follow up with his primary care physician. He was advised to sit and stay and get a ride home, which he did.  An incident report and VAERS report will be reported today.
This spontaneous report was received from a medical assistant concerning a patient of unknown age and gender. On 30-JUN-2014 the patient was vaccinated with ZOSTAVAX (single dose, Lot #000783, Expiration date: 30-APR-2014), subcutaneous. On 30-JUN-2014 the patient was inadvertently administered ZOSTAVAX that had expired on 30-APR-2014. The ZOSTAVAX had been stored in the patient's home freezer at an unknown temperature for 1 year prior to administration. No adverse effects were reported. Additional information has been requested.
From initial information received on 03/08/2005 from the patient's parent regarding an adverse event occurring in the USA, it was reported that a 12 year old male patient had a laceration wound to his finger and received a dose of TET TOX Booster USP vaccine, lot number not reported, administered in the left deltoid on 03/06/2005 at 10:00PM.  The route of administration was not reported.  Ten hours later, at 08:00AM on 03/07/2005, the patient was unable to move his left arm.  The site of injection was hardened and the patient had sever pain.  There was no redness, swelling or warmth at the site.  At the time of this report, the patient had not recovered from these events.
Patient reported, "I received my Covid 19 vaccination on Monday evening. I experienced a reaction immediately following. Within 10 minutes I had tachycardia (130s), high BP (160s), lightheadedness, nausea, headache, and feeling like I was going to faint. I was attended to by Ambulance paramedics. At the time of her report to her primary care provider on 1/7/2021, she was still having pretty significant side effects (headache, dizziness, and light sensitivity), enough so that I was staying home from work. These symptoms have now resolved.
I received the shot in left arm and in two weeks later I'm in hospital with an blood clot .; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 59-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 11Mar2021 at 13:00 as dose 1, single (Lot number: Eu6208) at the age of 58 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: THROMBOSIS (caused and prolonged hospitalization, medically significant) with onset 26Mar2021, outcome "not recovered", described as "I received the shot in left arm and in two weeks later I'm in hospital with an blood clot .". The patient was hospitalized and prolonged hospitalization for thrombosis (hospitalization duration: 7 day(s)). The events "i received the shot in left arm and in two weeks later i'm in hospital with an blood clot ." required physician office visit and emergency room visit. Therapeutic measures were taken as a result of thrombosis and treatment included blood thinners.  Clinical course: Patient did not received other vaccine within 4 weeks of Covid vaccine. Patient did not have covid prior to vaccination. Patient did not tested for Covid post vaccination.
This is a spontaneous report from a noncontactable consumer (patient). A 41-year-old male patient received the first dose of BNT162B2 (Pfizer-BioNTech COVID-19 mRNA vaccine; batch/lot# EL3247), at the age of 41, via an unspecified route of administration, in the right arm, on Mar 10, 2021, at 10:30, single dose, for COVID-19 immunisation. The patient did not have any medical history and known allergies. Prior to the vaccination, patient was not diagnosed with COVID-19. The patient did not receive any concomitant medication within two weeks of vaccination. The patient did not receive any other vaccines within four weeks prior to the vaccination. On Mar 11, 2021, patient experienced slight soreness in right deltoid and very mild fatigue. The events did not result in doctor or other healthcare professional office/clinic visits, emergency room/department or urgent care. No therapeutic measures taken as a result of the events. Since the vaccination, patient has not tested for COVID-19. The outcome of slight soreness in right deltoid and very mild fatigue: resolving (at the time of this report). No follow-up attempts possible. No further information expected.
Rash started on left thigh within 8 hours of receiving second Heatitis B vaccination.
Metaletic taste, chills, rash, fatigue, muscle pain and weakness, severe nausea and vomitting. Vomitted for 3 hrs. Vomitting occurred 48 hr after vaccination.
throat tightening & coughing & erythema;responded to DPH & Epi x 2 & dexamethasone & now on steroids;
Narrative: Other Relevant Hx: Symptoms: & SORENESS AT INJECTION SITE Treatment:
suspect acute inflammatory rxn lt upper extremity secondary to vax;ice, motrin rest, then heat p/2 days;
I have cosmetic fillers and my face was swollen at the site of fillers when I woke up this morning. Only my left side was swollen, as my doctor has told me in the past that they Injects much more filler on that side due to physiological differences that she is trying to balance.   I got these fillers I think july 2020  No other signs of side effects other than mild swelling od the left side of face. Took an antihistamine around 9:00am.
Patient got itchy within 15 minutes of receiving the vaccine. She mostly felt it on her back, when checked patient's skin was very dry. Skin was red and irritated on her back. Patient said her scalp felt itchy. Consulted with Dr, DO. Doctor gave orders to give benadryl 50mg orally. This was given and patient reported she felt better by 4:15 and left the facility.